autoimmune neuropathy/ nerve inflammation
Conditions
Interventions
Patients with GBS, CIDP and MMN will be treated according to the protocol of
the UMC Utrecht. These patients receive a cumulative dose of 2g/kg in 5
consecutive days. Neurological examination will b
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Age > 18 years Patients with GBS. Patients with CIDP (exacerbation) and MMN who were not treated at least three months prior to inclusion.
Exclusion criteria
Exclusion criteria: Other neuropathies (e.g. diabetic, porphiric, intoxication with medication or metal, vasculitic, Lyme neuroborreliosis, post-radiation, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies). Patients with an anaphylactic reaction to IVIg in the past.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The effect of IVIg on muscle strength and sensory modalities will be measured by comparing neurological examination after treatment (t=5, t=19, t=33) with neurological examination before treatment (t=1). The effects of IVIg treatment on complement component concentration will be measured in every serum sample to monitor the activity of this part of the humoral immune system before, during and after treatment. mRNA will be isolated from blood samples before and after treatment to obtain information about the influence of IVIg on leukocytes, create gene expression profiles and to observe whether there is a difference in expression before and after treatment (concerns cellular immune system). To analyze the sera in more detail, proteomics technology will be used. Surface enhanced laser desorption ionization time of flight (SELDI TOF) analysis allows reproducible measurements in large amounts of sera and is the most powerful method for biomarker identification at this moment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse effects | — |
Countries
Netherlands
Outcome results
None listed